ILC2-driven innate immune checkpoint mechanism antagonizes NK cell anti-metastatic function in the lung
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Metastasis constitutes the primary cause of cancer-related deaths, with the lung being a commonly affected organ. Here we found that activation of lung-resident group 2 innate lymphoid cells (ILC2) orchestrated suppression of Natural Killer (NK) cell-mediated innate anti-tumor immunity, leading to increased lung metastases and mortality. Using multiple models of lung metastasis, we show that IL-33-dependent ILC2-activation in the lung is centrally involved in promoting tumor burden. ILC2-driven innate type-2 inflammation is accompanied by profound local suppression of interferon-γ production and cytotoxic function of lung NK cells. ILC2-dependent suppression of NK cells is elaborated via an innate regulatory mechanism, reliant on IL-5-induced lung eosinophilia, ultimately limiting the metabolic fitness of NK cells. Therapeutic targeting of IL-33 or IL-5 reversed NK cell suppression, and alleviated cancer burden. Thus, we reveal an important function of IL-33 and ILC2 in promoting tumor metastasis via their capacity to suppress innate type-1 immunity.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1550-6606
Volume Title
Publisher
Publisher DOI
Rights
Sponsorship
European Molecular Biology Organization (EMBO) (ALTF 423-2017)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (840501)
Cancer Research UK (24995)